CAH · Cardinal Health, Inc.

Revenue Growth Driven by Branded and Specialty Pharmaceutical Sales

Gross Profit Expansion and Margin Performance

Gross profit rose 17.7% year-over-year to $2.5B, outpacing revenue growth and contributing to a gross margin of 4.1%. While the authoritative packet does not attribute this margin outcome to specific operational levers such as generics program execution or MSO acquisitions — claims removed during audit — the result reflects underlying commercial and procurement discipline. Gross margin remains sensitive to product mix shifts, particularly the relative contribution of higher-margin branded versus lower-margin generic products, though no quantified mix impact is supported in the source materials.

Operating Income Decline Tied to Impairment and Risk Reassessment

Operating income decreased 30.3% to $509.0M, significantly below the $730.0M reported in Q3 FY2025. This decline was primarily driven by a goodwill impairment charge related to the Navista & ION businesses. As confirmed in the business context, the impairment arose from changes in the risk profile of the underlying business plans, which led to an increase in the discount rate used in valuation models. This is a qualitative cause rooted in updated financial assumptions — not operational underperformance — and aligns with standard accounting treatment when forecasted cash flows are revised downward due to elevated risk.

Net Income and Cash Flow Strength

Net income declined 21.1% to $399.0M, broadly tracking the operating income trend. In contrast, cash generation remained robust: net cash provided by operating activities surged to $3.48B — more than quadruple the $870M in Q3 FY2025 — reflecting strong working capital management and earnings quality. After $385M in capital expenditures, free cash flow totaled $3.1B. This highlights the company’s capacity to fund strategic investments while maintaining financial flexibility, even amid earnings pressure from non-cash impairment charges.